$SUPN
SUPERNUS PHARMACEUTICALS, INC. Stock $supn

$supn Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000135657623000016 Filed on March 09, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$153.8M	$167.3M	$667.2M
YoY Change	0.82%	5.2%	15.09%
Cost Of Revenue	$23.46M	$22.95M	$87.22M
YoY Change	30.83%	35.07%	16.2%
Gross Profit	$130.3M	$144.4M	$580.0M
YoY Change	-3.17%	1.63%	14.92%
Gross Profit Margin	84.74%	86.28%	86.93%
Selling, General & Admin	$85.60M	$73.97M	$377.2M
YoY Change	-5.37%	-6.88%	23.78%
% of Gross Profit	65.69%	51.24%	65.04%
Research & Development	$21.21M	$17.77M	$74.55M
YoY Change	1.79%	-15.68%	-17.59%
% of Gross Profit	16.28%	12.31%	12.85%
Depreciation & Amortization	$20.60M	$20.85M	$85.54M
YoY Change	-3.56%	64.07%	162.44%
% of Gross Profit	15.81%	14.44%	14.75%
Operating Expenses	$106.8M	$110.0M	$451.8M
YoY Change	-4.03%	-3.18%	14.31%
Operating Profit	$5.176M	$34.33M	$46.12M
YoY Change	163.14%	20.9%	-46.39%
Interest Expense	$1.505M	$1.234M	$17.04M
YoY Change	-22.5%	-138.37%	-13.51%
% of Operating Profit	29.08%	3.59%	36.93%
Other Income/Expense, Net	$3.841M	-$428.0K	$14.62M
YoY Change	-69.89%	-48.5%	-213.73%
Pretax Income	$9.017M	$35.14M	$60.74M
YoY Change	-38.76%	1613.31%	-16.99%
Income Tax	-$7.900M	$9.659M	$32.00K
% Of Pretax Income	-87.61%	27.49%	0.05%
Net Earnings	$16.95M	$25.48M	$60.71M
YoY Change	-33.84%	943.45%	13.64%
Net Earnings / Revenue	11.02%	15.23%	9.1%
Basic Earnings Per Share	$0.31		$1.13
Diluted Earnings Per Share	$0.29	$0.41	$1.04
COMMON SHARES
Basic Shares Outstanding	54.38M shares	54.06M shares	53.67M shares
Diluted Shares Outstanding	62.45M shares		61.68M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$228.6M	$461.3M	$461.3M
YoY Change	-26.79%	35.81%	35.81%
Cash & Equivalents	$58.44M	$93.12M	$93.12M
Short-Term Investments	$170.1M	$368.2M	$368.2M
Other Short-Term Assets	$420.1M	$15.78M	$15.78M
YoY Change	1777.6%	-41.6%	-41.6%
Inventory	$91.15M	$91.54M	$91.54M
Prepaid Expenses
Receivables	$143.6M	$165.5M	$165.5M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$883.3M	$734.2M	$734.2M
YoY Change	55.38%	22.04%	22.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.61M	$15.17M	$44.08M
YoY Change	-15.13%	-10.51%	-15.75%
Goodwill	$117.0M	$117.0M
YoY Change	1.39%	-0.42%
Intangibles	$682.5M	$702.5M
YoY Change	-10.67%	-10.48%
Long-Term Investments	$54.16M	$93.90M	$93.90M
YoY Change	-56.79%	-21.21%	-21.21%
Other Assets	$40.18M	$39.81M	$10.90M
YoY Change	-17.97%	-19.15%	-21.38%
Total Long-Term Assets	$908.5M	$968.4M	$968.4M
YoY Change	-15.18%	-10.96%	-10.96%
TOTAL ASSETS
Total Short-Term Assets	$883.3M	$734.2M	$734.2M
Total Long-Term Assets	$908.5M	$968.4M	$968.4M
Total Assets	$1.792B	$1.703B	$1.703B
YoY Change	9.29%	0.79%	0.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.54M	$10.54M	$10.54M
YoY Change	-6.32%	12.99%	12.99%
Accrued Expenses	$95.35M	$96.34M	$237.5M
YoY Change	6.61%	-18.13%	-1.5%
Deferred Revenue
YoY Change
Short-Term Debt	$480.9M	$402.0M	$402.0M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$731.5M	$688.0M	$688.0M
YoY Change	157.08%	118.14%	118.14%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$8.614M	$8.692M	$78.54M
YoY Change	-39.1%	-46.94%	-15.84%
Total Long-Term Liabilities	$8.614M	$8.692M	$78.54M
YoY Change	-39.1%	-97.8%	-83.38%
TOTAL LIABILITIES
Total Short-Term Liabilities	$731.5M	$688.0M	$688.0M
Total Long-Term Liabilities	$8.614M	$8.692M	$78.54M
Total Liabilities	$879.7M	$816.3M	$816.3M
YoY Change	8.46%	-6.53%	-6.53%
SHAREHOLDERS EQUITY
Retained Earnings	$498.2M	$481.2M
YoY Change	11.66%	26.67%
Common Stock	$54.00K	$54.00K
YoY Change	1.89%	1.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$912.2M	$886.2M	$886.2M
YoY Change
Total Liabilities & Shareholders Equity	$1.792B	$1.703B	$1.703B
YoY Change	9.29%	0.79%	0.79%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	$16.95M	$25.48M	$60.71M
YoY Change	-33.84%	943.45%	13.64%
Depreciation, Depletion And Amortization	$20.60M	$20.85M	$85.54M
YoY Change	-3.56%	64.07%	162.44%
Cash From Operating Activities	$49.13M	$27.56M	$116.8M
YoY Change	1041.93%	-43.47%	-8.1%
INVESTING ACTIVITIES
Capital Expenditures	$278.0K	-$10.00K	$412.0K
YoY Change	-132.67%	-75.0%	-120.15%
Acquisitions			$0.00
YoY Change			-100.0%
Other Investing Activities	$240.1M	-$48.78M	-$216.3M
YoY Change	-447.23%	-164.03%	170.76%
Cash From Investing Activities	$239.8M	-$48.77M	-$216.7M
YoY Change	-442.61%	-164.05%	164.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$12.42M
YoY Change			75.1%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$80.17M	2.829M	-$10.48M
YoY Change	-463.86%	-102.07%	-91.97%
NET CHANGE
Cash From Operating Activities	$49.13M	27.56M	$116.8M
Cash From Investing Activities	$239.8M	-48.77M	-$216.7M
Cash From Financing Activities	$80.17M	2.829M	-$10.48M
Net Change In Cash	$369.1M	-18.37M	-$110.3M
YoY Change	-520.75%	55.08%	29.47%
FREE CASH FLOW
Cash From Operating Activities	$49.13M	$27.56M	$116.8M
Capital Expenditures	$278.0K	-$10.00K	$412.0K
Free Cash Flow	$48.85M	$27.57M	$116.4M
YoY Change	847.95%	-43.5%	-9.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001356576
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member
CY2022	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2022#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-35518
CY2022	dei	Entity Registrant Name EntityRegistrantName	SUPERNUS PHARMACEUTICALS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-2590184
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	9715 Key West Avenue
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
CY2022	dei	City Area Code CityAreaCode	(301)
CY2022	dei	Local Phone Number LocalPhoneNumber	838-2500
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.001 Par Value
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54376904	shares
CY2022	dei	Trading Symbol TradingSymbol	SUPN
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	1545750083	usd
CY2022	dei	Auditor Firm AuditorFirmId	185
CY2022	dei	Auditor Name AuditorName	KPMG LLP
CY2022	dei	Auditor Location AuditorLocation	Baltimore, Maryland
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	93120000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	203434000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	368214000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	136246000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	165497000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	148932000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	91541000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	85959000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15779000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	27019000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	734151000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	601590000	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	93896000	usd
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	119166000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	15173000	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	16955000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	702463000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	784693000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	117019000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	117516000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	39806000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	49232000	usd
CY2022Q4	us-gaap	Assets Assets	1702508000	usd
CY2021Q4	us-gaap	Assets Assets	1689152000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	96342000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	117683000	usd
CY2022Q4	supn	Accrued Product Returns And Rebates AccruedProductReturnsAndRebates	151665000	usd
CY2021Q4	supn	Accrued Product Returns And Rebates AccruedProductReturnsAndRebates	132724000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	21120000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	44840000	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	401968000	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	16863000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	20132000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	687958000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	315379000	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	usd
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	379252000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	33847000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	35637000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	35998000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	41298000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	49809000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	85355000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8692000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16380000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	816304000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	873301000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	815851000	usd
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54253796	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54253796	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53256094	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53256094	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	54000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	53000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	408115000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	434337000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3210000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1539000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	481245000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	379922000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	886204000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1702508000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1689152000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	667238000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	579775000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	520397000	usd
CY2022	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	87221000	usd
CY2021	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	75061000	usd
CY2020	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	52459000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	74552000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	90467000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	75961000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	377221000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	304759000	usd
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	200677000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	82630000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	29989000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15702000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-510000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-6530000	usd
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1900000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	621114000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	493746000	usd
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	346699000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	46124000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	86029000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	173698000	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	21689000	usd
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	10569000	usd
CY2020	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	18704000	usd
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	7070000	usd
CY2021	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	23423000	usd
CY2020	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	23754000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	14619000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12854000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5050000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	60743000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	73175000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	168648000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19751000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	41698000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	60711000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	53424000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	126950000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.13
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.01
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.41
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.04
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.98
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.36
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53665143	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53099330	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52615269	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61679800	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54356744	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53689743	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	60711000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	53424000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	126950000	usd
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-4749000	usd
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-7436000	usd
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1558000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4749000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-7436000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1558000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	55962000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	45988000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	128508000	usd
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	595428000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16561000	usd
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4361000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	126950000	usd
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1558000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	744858000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17910000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7095000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	53424000	usd
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-7436000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	815851000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17568000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12423000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	60711000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	60711000	usd
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-4749000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	886204000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	60711000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	53424000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	126950000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	85543000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	32595000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18141000	usd
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	usd
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	15000000	usd
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	usd
CY2022	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	12888000	usd
CY2021	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0	usd
CY2020	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2112000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	17501000	usd
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	16581000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	17568000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	17910000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	16561000	usd
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	14000	usd
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	347000	usd
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	4352000	usd
CY2022	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-3233000	usd
CY2021	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-418000	usd
CY2020	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	2889000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-510000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-6530000	usd
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1900000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-11638000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1420000	usd
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1454000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-26324000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4994000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	568000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16366000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3867000	usd
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	34607000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	17858000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14580000	usd
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10124000	usd
CY2022	supn	Increase Decrease In Prepaid Deferred Expense And Other Current Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets	-12303000	usd
CY2021	supn	Increase Decrease In Prepaid Deferred Expense And Other Current Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets	8398000	usd
CY2020	supn	Increase Decrease In Prepaid Deferred Expense And Other Current Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets	10442000	usd
CY2022	supn	Increase Decrease In Accrued Product Returns And Rebates IncreaseDecreaseInAccruedProductReturnsAndRebates	18941000	usd
CY2021	supn	Increase Decrease In Accrued Product Returns And Rebates IncreaseDecreaseInAccruedProductReturnsAndRebates	4502000	usd
CY2020	supn	Increase Decrease In Accrued Product Returns And Rebates IncreaseDecreaseInAccruedProductReturnsAndRebates	10386000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-19163000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	18179000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8272000	usd
CY2022	supn	Increase Decrease In Contingent Consideration IncreaseDecreaseInContingentConsideration	-2100000	usd
CY2021	supn	Increase Decrease In Contingent Consideration IncreaseDecreaseInContingentConsideration	0	usd
CY2020	supn	Increase Decrease In Contingent Consideration IncreaseDecreaseInContingentConsideration	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	116826000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	127127000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	138399000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	190739000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	530509000	usd
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	378422000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	406990000	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	311573000	usd
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	95890000	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	950000	usd
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	298541000	usd
CY2022	us-gaap	Payments To Acquire Business Two Net Of Cash Acquired PaymentsToAcquireBusinessTwoNetOfCashAcquired	0	usd
CY2021	us-gaap	Payments To Acquire Business Two Net Of Cash Acquired PaymentsToAcquireBusinessTwoNetOfCashAcquired	310742000	usd
CY2020	us-gaap	Payments To Acquire Business Two Net Of Cash Acquired PaymentsToAcquireBusinessTwoNetOfCashAcquired	0	usd
CY2022	supn	Distributions From Collaborative Arrangement Investment DistributionsFromCollaborativeArrangementInvestment	0	usd
CY2021	supn	Distributions From Collaborative Arrangement Investment DistributionsFromCollaborativeArrangementInvestment	-12888000	usd
CY2020	supn	Distributions From Collaborative Arrangement Investment DistributionsFromCollaborativeArrangementInvestment	15000000	usd
CY2022	supn	Payments To Acquire Property Plant And Equipment And Deferred Legal Fees PaymentsToAcquirePropertyPlantAndEquipmentAndDeferredLegalFees	412000	usd
CY2021	supn	Payments To Acquire Property Plant And Equipment And Deferred Legal Fees PaymentsToAcquirePropertyPlantAndEquipmentAndDeferredLegalFees	2045000	usd
CY2020	supn	Payments To Acquire Property Plant And Equipment And Deferred Legal Fees PaymentsToAcquirePropertyPlantAndEquipmentAndDeferredLegalFees	3690000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-216663000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-81913000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-34699000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12423000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7095000	usd
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4361000	usd
CY2022	supn	Proceeds From Governmental Loans And Grants ProceedsFromGovernmentalLoansAndGrants	0	usd
CY2021	supn	Proceeds From Governmental Loans And Grants ProceedsFromGovernmentalLoansAndGrants	800000	usd
CY2020	supn	Proceeds From Governmental Loans And Grants ProceedsFromGovernmentalLoansAndGrants	0	usd
CY2022	us-gaap	Repayments Of Assumed Debt RepaymentsOfAssumedDebt	0	usd
CY2021	us-gaap	Repayments Of Assumed Debt RepaymentsOfAssumedDebt	138315000	usd
CY2020	us-gaap	Repayments Of Assumed Debt RepaymentsOfAssumedDebt	0	usd
CY2022	supn	Purchases Of Convertible Note Hedge PurchasesOfConvertibleNoteHedge	0	usd
CY2021	supn	Purchases Of Convertible Note Hedge PurchasesOfConvertibleNoteHedge	0	usd
CY2020	supn	Purchases Of Convertible Note Hedge PurchasesOfConvertibleNoteHedge	802000	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	22900000	usd
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2020	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-10477000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-130420000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3559000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-110314000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-85206000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	107259000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	203434000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	288640000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	181381000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93120000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	203434000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	288640000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2516000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	2516000	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	2516000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	12883000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	11908000	usd
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	6949000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	16200000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	25190000	usd
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	45428000	usd
CY2022	supn	Business Combination Contingent Consideration Arrangements Acquisition Liability BusinessCombinationContingentConsiderationArrangementsAcquisitionLiability	0	usd
CY2021	supn	Business Combination Contingent Consideration Arrangements Acquisition Liability BusinessCombinationContingentConsiderationArrangementsAcquisitionLiability	10307000	usd
CY2020	supn	Business Combination Contingent Consideration Arrangements Acquisition Liability BusinessCombinationContingentConsiderationArrangementsAcquisitionLiability	76700000	usd
CY2022	supn	Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability	1867000	usd
CY2021	supn	Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability	10868000	usd
CY2020	supn	Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability	2478000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability		usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	22747000	usd
CY2022	supn	Property And Equipment Additions From Utilization Of Tenant Improvement Allowance PropertyAndEquipmentAdditionsFromUtilizationOfTenantImprovementAllowance	580000	usd
CY2021	supn	Property And Equipment Additions From Utilization Of Tenant Improvement Allowance PropertyAndEquipmentAdditionsFromUtilizationOfTenantImprovementAllowance	25000	usd
CY2020	supn	Property And Equipment Additions From Utilization Of Tenant Improvement Allowance PropertyAndEquipmentAdditionsFromUtilizationOfTenantImprovementAllowance	0	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	Organization and Business<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supernus Pharmaceuticals, Inc. (the Company) was incorporated in Delaware and commenced operations in 2005. The Company is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug induced extrapyramidal reactions in adult patients. The Company is developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has eight commercial products: Trokendi XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Oxtellar XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Qelbree</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, APOKYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, XADAGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MYOBLOC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GOCOVRI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Osmolex ER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, SPN-830 (apomorphine infusion device) is a late-stage drug/device combination product candidate for the continuous treatment of motor fluctuations ("off" episodes) in PD patients that are not adequately controlled with oral levodopa and one or more adjunct PD medications.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adamas Acquisition and Reorganization</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2021, the Company entered into an Agreement and Plan of Merger by and among the Company, Adamas Pharmaceuticals, Inc. (Adamas) and Supernus Reef, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (Purchaser) (Adamas Agreement). On November 24, 2021 (the Closing Date), the Company completed its purchase of all of the outstanding equity of Adamas, pursuant to the Adamas Agreement dated October 10, 2021, and the Purchaser was merged with and into Adamas (the Merger), with Adamas continuing as the surviving corporation in the Merger as a wholly-owned subsidiary of the Company (Adamas Acquisition). On the Closing Date, Adamas owned two marketed products: GOCOVRI (amantadine) extended-release capsules, the first and only FDA approved medicine indicated for the treatment of both "off" episodes and dyskinesia in patients with PD receiving levodopa-based therapy and as an adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes; and Osmolex ER (amantadine) extended-release tablets, approved for the treatment of PD and drug-induced extrapyramidal reactions in adult patients. Adamas also owns the right to receive royalties from Allergan plc for sales of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) in the U.S.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022 and subsequent to the Adamas Acquisition, the Company completed a reorganization of the Adamas legal entities in an effort to obtain operational, legal and other benefits that also resulted in certain state tax efficiencies. The reorganization had no effect on the consolidated financial statements other than certain state tax efficiencies. (See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.)</span></div>
CY2022	supn	Number Of Commercial Products NumberOfCommercialProducts	8	product
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition and results of operations is highly uncertain and subject to change. As a result, certain of our estimates and assumptions, including the provision for sales deductions, the fair values of financial instruments and the recoverability of intangible assets, require increased judgment and carry a higher degree of variability and volatility that could result in material changes to our estimates in future periods.</span></div>
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk concentrations consist of cash, cash equivalents, marketable securities, and accounts receivable. The counterparties are various corporations, governmental institutions, and financial institutions of high credit standing.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's cash, cash equivalents, and marketable securities are maintained in U.S. government agency debt and debt of well-known, investment grade corporations. Deposits held with banks may exceed the amount of governmental insurance provided on such deposits. Generally, these deposits may be redeemed upon demand, and therefore, these bear minimal default risk.</span></div>
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2022	supn	Sales Return Period Prior To Expiration SalesReturnPeriodPriorToExpiration	P6M
CY2022	supn	Sales Return Period SalesReturnPeriod	P12M
CY2022	supn	Sales Return Period SalesReturnPeriod	P12M
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2022	us-gaap	Advertising Expense AdvertisingExpense	131700000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	86000000	usd
CY2020	us-gaap	Advertising Expense AdvertisingExpense	54500000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent	466333000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	667238000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	579775000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	520397000	usd
CY2022	supn	Revenue From Royalty Agreement RevenueFromRoyaltyAgreement	9800000	usd
CY2021	supn	Revenue From Royalty Agreement RevenueFromRoyaltyAgreement	9400000	usd
CY2020	supn	Revenue From Royalty Agreement RevenueFromRoyaltyAgreement	8500000	usd
CY2021	supn	Contract With Customer Prior Year Sale Adjustments Percentage ContractWithCustomerPriorYearSaleAdjustmentsPercentage	0.01
CY2022	supn	Contract With Customer Prior Year Sale Adjustments Percentage ContractWithCustomerPriorYearSaleAdjustmentsPercentage	0.01
CY2020	supn	Contract With Customer Change In Refund Liability ContractWithCustomerChangeInRefundLiability	13800000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent	253301000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	14000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2349000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4237000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	238000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	462110000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	255412000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	368214000	usd
CY2022Q4	supn	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year One To Year Two DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneToYearTwo	77584000	usd
CY2022Q4	supn	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year Two To Year Three DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwoToYearThree	16312000	usd
CY2022Q4	supn	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year Three To Year Four DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThreeToYearFour	0	usd
CY2022Q4	supn	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year Four DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFour	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	462110000	usd
CY2021Q4	us-gaap	Proceeds From Divestiture Of Businesses And Interests In Affiliates ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates	12900000	usd
CY2022Q1	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	12900000	usd
CY2020Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	230000000	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	22900000	usd
CY2022	supn	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Excess Acquisition Date Fair Value BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationExcessAcquisitionDateFairValue	2100000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	80477000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	25000000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-510000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	54967000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	54967000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	21120000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	44840000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	33847000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	35637000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	54967000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	80477000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	117516000	usd
CY2022	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-497000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	117019000	usd
CY2022	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P7Y8M19D
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	849320000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	146857000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	702463000	usd
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	848920000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	64227000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	784693000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	82600000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	30000000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15700000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	79865000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	79865000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	75198000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	74974000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	73205000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	195356000	usd
CY2018Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	80.91
CY2022Q4	supn	Votes Per Common Share Number VotesPerCommonShareNumber	1	vote
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	2000000	shares
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17568000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17910000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16561000	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	146400	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	625100	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	69500	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	625100	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	80.91
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	80.91
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1257414	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1074474	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	60711000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	53424000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	126950000	usd
CY2022	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	3556000	usd
CY2021	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	usd
CY2020	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	64267000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	53424000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	126950000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53665143	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53099330	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52615269	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1230721	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	6783936	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61679800	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54356744	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53689743	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.13
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.01
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.41
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.04
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.98
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.36
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	17515000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	16606000	usd
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	29893000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	8846000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	8196000	usd
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	11234000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-6802000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1651000	usd
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	2200000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-19527000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3400000	usd
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1629000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19751000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	41698000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-314000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	12756000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	15367000	usd
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	35417000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3198000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	3088000	usd
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	7281000	usd
CY2022	supn	Effective Income Tax Rate Reconciliation Permanent Items Amount EffectiveIncomeTaxRateReconciliationPermanentItemsAmount	399000	usd
CY2021	supn	Effective Income Tax Rate Reconciliation Permanent Items Amount EffectiveIncomeTaxRateReconciliationPermanentItemsAmount	1465000	usd
CY2020	supn	Effective Income Tax Rate Reconciliation Permanent Items Amount EffectiveIncomeTaxRateReconciliationPermanentItemsAmount	2654000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-237000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1016000	usd
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3602000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-1992000	usd
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	348000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-8626000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	250000	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	456000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	911000	usd
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-400000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19751000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	41698000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	112516000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	126333000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	23300000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	19506000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	15422000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	17802000	usd
CY2022Q4	supn	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	13926000	usd
CY2021Q4	supn	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	0	usd
CY2022Q4	supn	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	10821000	usd
CY2021Q4	supn	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	12146000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	4946000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	7819000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	3620000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	7730000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3070000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4448000	usd
CY2022Q4	supn	Deferred Tax Assets Convertible Bond Hedge DeferredTaxAssetsConvertibleBondHedge	1449000	usd
CY2021Q4	supn	Deferred Tax Assets Convertible Bond Hedge DeferredTaxAssetsConvertibleBondHedge	6910000	usd
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	45000	usd
CY2021Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	7860000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5356000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4256000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	194471000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	214810000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	59598000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	70529000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	134873000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	144281000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	162654000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	199240000	usd
CY2022Q4	supn	Deferred Tax Liabilities Debt Discount On Convertible Notes DeferredTaxLiabilitiesDebtDiscountOnConvertibleNotes	133000	usd
CY2021Q4	supn	Deferred Tax Liabilities Debt Discount On Convertible Notes DeferredTaxLiabilitiesDebtDiscountOnConvertibleNotes	5671000	usd
CY2022Q4	supn	Deferred Tax Liabilities Infringement Legal Cost DeferredTaxLiabilitiesInfringementLegalCost	10968000	usd
CY2021Q4	supn	Deferred Tax Liabilities Infringement Legal Cost DeferredTaxLiabilitiesInfringementLegalCost	10689000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	7338000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	9099000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3589000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4937000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	184682000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	229636000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	49809000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	85355000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	70529000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	582000	usd
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11000	usd
CY2022	supn	Deferred Tax Assets Valuation Allowance Increase From Acquisition Accounting DeferredTaxAssetsValuationAllowanceIncreaseFromAcquisitionAccounting	-2305000	usd
CY2021	supn	Deferred Tax Assets Valuation Allowance Increase From Acquisition Accounting DeferredTaxAssetsValuationAllowanceIncreaseFromAcquisitionAccounting	69697000	usd
CY2020	supn	Deferred Tax Assets Valuation Allowance Increase From Acquisition Accounting DeferredTaxAssetsValuationAllowanceIncreaseFromAcquisitionAccounting	573000	usd
CY2022	supn	Deferred Tax Assets Valuation Allowance Additions DeferredTaxAssetsValuationAllowanceAdditions	435000	usd
CY2021	supn	Deferred Tax Assets Valuation Allowance Additions DeferredTaxAssetsValuationAllowanceAdditions	250000	usd
CY2020	supn	Deferred Tax Assets Valuation Allowance Additions DeferredTaxAssetsValuationAllowanceAdditions	0	usd
CY2022	supn	Deferred Tax Assets Valuation Allowance Reductions DeferredTaxAssetsValuationAllowanceReductions	9061000	usd
CY2021	supn	Deferred Tax Assets Valuation Allowance Reductions DeferredTaxAssetsValuationAllowanceReductions	0	usd
CY2020	supn	Deferred Tax Assets Valuation Allowance Reductions DeferredTaxAssetsValuationAllowanceReductions	2000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	59598000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	70529000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	582000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	70500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	9100000	usd
CY2022Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	0	usd
CY2021Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	1600000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6100000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5881000	usd
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5978000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	32000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	898000	usd
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1027000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	221000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	39000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	363000	usd
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1770000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	316000	usd
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1345000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4323000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6100000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5881000	usd
CY2022	supn	Income Tax Expense On Uncertain Tax Position Alternate Minimum Tax IncomeTaxExpenseOnUncertainTaxPositionAlternateMinimumTax	1700000	usd
CY2021	supn	Income Tax Expense On Uncertain Tax Position Alternate Minimum Tax IncomeTaxExpenseOnUncertainTaxPositionAlternateMinimumTax	100000	usd
CY2020	supn	Income Tax Expense On Uncertain Tax Position Alternate Minimum Tax IncomeTaxExpenseOnUncertainTaxPositionAlternateMinimumTax	600000	usd
CY2022	supn	Income Tax Expense On Uncertain Tax Position IncomeTaxExpenseOnUncertainTaxPosition	30000	usd
CY2021	supn	Income Tax Expense On Uncertain Tax Position IncomeTaxExpenseOnUncertainTaxPosition	300000	usd
CY2020	supn	Income Tax Expense On Uncertain Tax Position IncomeTaxExpenseOnUncertainTaxPosition	300000	usd
CY2022	supn	Unrecognized Tax Benefits Increase Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsIncreaseResultingFromLapseOfApplicableStatuteOfLimitations	40000	usd
CY2019Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P10Y
CY2021Q4	supn	Lessee Operating Lease Number Of Renewal Options LesseeOperatingLeaseNumberOfRenewalOptions	1	renewaloption
CY2021Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	28904000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	35365000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	28904000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	35365000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6791000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6477000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	35998000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	41298000	usd
CY2022Q4	supn	Lease Liability LeaseLiability	42789000	usd
CY2021Q4	supn	Lease Liability LeaseLiability	47775000	usd
CY2022	supn	Operating Lease Fixed Lease Cost OperatingLeaseFixedLeaseCost	8239000	usd
CY2021	supn	Operating Lease Fixed Lease Cost OperatingLeaseFixedLeaseCost	8929000	usd
CY2022	supn	Operating Lease Variable Lease Cost OperatingLeaseVariableLeaseCost	4608000	usd
CY2021	supn	Operating Lease Variable Lease Cost OperatingLeaseVariableLeaseCost	3059000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	12847000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	11988000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	12883000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	11908000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1867000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	10868000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y4M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.038
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8257000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	7645000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5672000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4527000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	4585000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	20071000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	50757000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7968000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	42789000	usd
CY2022Q4	supn	Allowance For Expected Sales Deductions AllowanceForExpectedSalesDeductions	13000000	usd
CY2021Q4	supn	Allowance For Expected Sales Deductions AllowanceForExpectedSalesDeductions	13500000	usd
CY2022Q4	us-gaap	Inventory Work In Process And Raw Materials Net Of Reserves InventoryWorkInProcessAndRawMaterialsNetOfReserves	24820000	usd
CY2021Q4	us-gaap	Inventory Work In Process And Raw Materials Net Of Reserves InventoryWorkInProcessAndRawMaterialsNetOfReserves	7325000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	31710000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	45711000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	35011000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	32923000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	91541000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	85959000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	28222000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	33409000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13049000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16454000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15173000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16955000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3000000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2600000	usd
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4300000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10543000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9331000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	16963000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	28068000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	16783000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	26728000	usd
CY2022Q4	supn	Accrued Product Costs Current AccruedProductCostsCurrent	15216000	usd
CY2021Q4	supn	Accrued Product Costs Current AccruedProductCostsCurrent	18460000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	12022000	usd
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	13821000	usd
CY2022Q4	supn	Accrued Clinical Trial And Clinical Supply Costs Current AccruedClinicalTrialAndClinicalSupplyCostsCurrent	7490000	usd
CY2021Q4	supn	Accrued Clinical Trial And Clinical Supply Costs Current AccruedClinicalTrialAndClinicalSupplyCostsCurrent	9125000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6791000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6477000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10534000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5673000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	96342000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	117683000	usd
CY2022Q4	supn	Accrued Rebates AccruedRebates	106657000	usd
CY2021Q4	supn	Accrued Rebates AccruedRebates	97597000	usd
CY2022Q4	supn	Accrued Product Returns AccruedProductReturns	45008000	usd
CY2021Q4	supn	Accrued Product Returns AccruedProductReturns	35127000	usd
CY2022Q4	supn	Accrued Product Returns And Rebates AccruedProductReturnsAndRebates	151665000	usd
CY2021Q4	supn	Accrued Product Returns And Rebates AccruedProductReturnsAndRebates	132724000	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	4654000	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	19696000	usd
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	19435000	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	2416000	usd
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	3727000	usd
CY2020	us-gaap	Interest Expense Other InterestExpenseOther	4319000	usd
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	7070000	usd
CY2021	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	23423000	usd
CY2020	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	23754000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2100000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	17500000	usd
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	16600000	usd
CY2014Q3	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	30000000	usd

Files In Submission

Name	View Source	Status
0001356576-23-000016-index-headers.html	Edgar Link	pending
0001356576-23-000016-index.html	Edgar Link	pending
0001356576-23-000016.txt	Edgar Link	pending
0001356576-23-000016-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
supn-20201231xex1071.htm	Edgar Link	pending
supn-20221231.htm	Edgar Link	pending
supn-20221231.xsd	Edgar Link	pending
supn-20221231xex21.htm	Edgar Link	pending
supn-20221231xex231.htm	Edgar Link	pending
supn-20221231xex311.htm	Edgar Link	pending
supn-20221231xex312.htm	Edgar Link	pending
supn-20221231xex321.htm	Edgar Link	pending
supn-20221231xex322.htm	Edgar Link	pending
supn-20221231_g1.jpg	Edgar Link	pending
supn-20221231_cal.xml	Edgar Link	unprocessable
supn-20221231_def.xml	Edgar Link	unprocessable
supn-20221231_pre.xml	Edgar Link	unprocessable
supn-20221231_lab.xml	Edgar Link	unprocessable
supn-20221231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SUPN
SUPERNUS PHARMACEUTICALS, INC. Stock $supn

2023 Q1 Form 10-K Financial Statement

#000135657623000016 Filed on March 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SUPN SUPERNUS PHARMACEUTICALS, INC. Stock $supn

2023 Q1 Form 10-K Financial Statement

#000135657623000016 Filed on March 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SUPN
SUPERNUS PHARMACEUTICALS, INC. Stock $supn